A Pilot Study of the Cyclin Dependent Kinases 4, 6 Inhibitor Ribociclib in Patients with Foregut Neuroendocrine Tumors

#2165

Introduction: Increased cyclin dependent kinases 4, 6 (cdk 4/6) activity is noted in the majority of well differentiated foregut neuroendocrine tumors (fNETs) due to mutations in MENIN and other aberrations. These tumors also have preserved Rb function making cdk 4/6 inhibitors attractive agents for therapy.

Aim(s): To evaluate the activity of the oral cdk 4/6 inhibitor, ribociclib (R) in fNETs To evaluate the pharmacodynamic activity of R in paired biopsies at baseline and cycle (c) 2 day 1

Materials and methods: In this single institution study, 20 patients (pts) with advanced, progressive fNETs were treated with R 600 mg by mouth daily for 3 weeks (w) and off for 1w in 4w cycles (c). Pancreatic NET (pNET) patients were required to have progression on prior therapy. Re-staging scans were obtained every 3c.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Dasari A

Authors: Dasari A, Halperin D, Coya T, Mahvash A, Zorrilla I,

Keywords: Foregut NETs, ribociclib, cdk 4/6,